loader2
Partner With Us NRI

Strides Pharma Science Ltd share Price Today

Company details

940.00
990.00
396.45
990.00
6M Return 67.82%
1Y Return 140.41%
Mkt Cap.(Cr) 8,994.25
Volume 1,166,874
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 1,166,874

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Strides Pharma Science announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Highest ever quarterly Revenue of Rs 10,583 million
  • Gross Margin returned to a historic high of 60.7% in Q4FY24
  • Highest ever quarterly EBITDA of Rs 2,040 million

FY24 Financial Highlights:

  • Highest ever full-year Revenue of Rs 40,555 million in FY24, up 14.4% YoY
  • Highest ever full-year EBITDA of Rs 7,477 million in FY24, up 77.6% YoY
  • US business achieved top end of USD 250 million revenue outlook for FY24, grew by 11.8% YoY
  • Net Debt reduced by Rs 3,131 million in FY24
  • Net Debt to EBITDA improved to 2.72x in FY24

Arun Kumar, Founder, Executive Chairperson & Managing Director, commented on the performance and said, “FY24 was an exceptional year for Strides, marked by the successful completion of our Reset strategy initiated in FY22. The company achieved all its key objectives laid down in our Reset strategy and has bounced back to become a strong and resilient company.

As a result of our focus on consistent growth and cost containment, FY24 concluded as the best year in the Company’s history in terms of both Revenue and absolute EBITDA.

With today’s leadership announcement, we have introduced a well-structured succession and leadership development program, guided by the Board. I am confident that the strong internal talent we have developed over the years will ensure the company's continued long-term growth. In the near term, we will continue to focus on operating cash flows while investing in growth to ensure that the efforts of our Reset are balanced by an improved revenue CAGR, in the coming years. Our ESG efforts have started to yield results, with our EcoVadis rating improving from 30 to 44 during the first year of review. We will continue to intensify our efforts to become a more sustainable and responsible company”.

Result PDF

View Other Company Results

Strides Pharma Science Ltd shares SWOT Analysis

Strengths (12)

  • Strong Momentum: Price above short, medium and long term moving averages
  • New 52 week high today
  • Effectively using its capital to generate profit - RoCE improving in last 2 years

Weakness (5)

  • Promoters increased pledged shares QoQ
  • MFs decreased their shareholding last quarter
  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (4)

  • Highest Recovery from 52 Week Low
  • Stock with Low PE (PE < = 10)
  • RSI indicating price strength

Threats (2)

  • Promoter decreasing their shareholding
  • Red Flags: Firms linked to ongoing regulatory investigations/legal cases

Resistance and support

R1 999.1
R2 1,019.6
R3 1,049.1
Pivot

969.57

S1 949.1
S2 919.6
S3 899.1
EMA SMA
890.5
859.0
803.6
703.9
878.0
865.1
814.5
672.7
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
AMANSA HOLDING PRIVATE LTD. Bulk Purchase 2024-02-09 713 1140301 BSE
BAJAJ FINANCE LIMITED Bulk Sell 2024-02-09 713 804629 BSE
AMANSA HOLDING PRIVATE LTD. Block Purchase 2024-02-09 713 563829 BSE
Name Category Shares
ARUN KUMAR PILLAI PROMOTER 2.11%
K R RAVISHANKAR PROMOTER 1.37%
PRONOMZ VENTURES LLP PROMOTER 17.18%
KARUNA BUSINESS SOLUTIONS LLP PROMOTER 3.51%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Strides Pharma Science Ltd Stocks COMPARISON

Financials( in Cr) Strides Pharma Science Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 978.70 1,516.00 1,564.75 4,588.60 1,109.55
% Change 3.92 0.34 1.31 -0.11 1.75
Mcap Cr 8,994.25 363,739.19 126,332.75 121,813.11 111,646.69
Revenue TTM Cr 3,688.39 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr -212.33 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 321.54 36.20 29.27 76.21 28.46
1 Year Return 140.41 53.43 59.42 31.57 114.34
ROCE 0.00 16.79 14.76 19.30 16.25
ROE 0.00 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 2,195.16 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 35,930.46 -6,140.05
LAST 3M 112,173.55 -45,499.40
LAST 6M 183,830.47 -16,034.02
LAST 12M 290,122.07 99,526.79

Strides Pharma Science Ltd Information

Stock PE (TTM)
321.54
Promoter Holding
25.88%
Book Value
231.2503
ROCE
0%
ROE
0%
Registered Address

No 201 Devavrata Sector 17, Vashi, Navi Mumbai, Maharashtra, 400703

Tel : 91-22-27892924/27893199
Email : investors:strides.com
Website : http://www.strides.com
Registrar

Karvy Computershare Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 532531
NSE Code : STAR
Book Closure Date (Month) :
BSE Group : A
ISIN : INE939A01011

FAQ’s on Strides Pharma Science Ltd Shares

You can buy Strides Pharma Science Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Strides Pharma Science Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 14, 2024 03:57 PM the closing price of Strides Pharma Science Ltd was Rs.978.70.

The latest PE ratio of Strides Pharma Science Ltd as of Jun 14, 2024 03:57 PM is 321.54

The latest PB ratio of Strides Pharma Science Ltd as of Jun 14, 2024 03:57 PM is 0.25

The 52-week high of Strides Pharma Science Ltd share price is Rs. 990.00 while the 52-week low is Rs. 396.45

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 14, 2024 03:57 PM, the market cap of Strides Pharma Science Ltd stood at Rs. 8,994.25.

Download App

Download Our App

Play Store App Store
market app